Randomized, phase I/II study of gemcitabine plus IGF-1R antagonist (MK-0646) versus gemcitabine plus erlotinib with and without MK-0646 for advanced pancreatic adenocarcinoma

Randomized, phase I/II study of gemcitabine plus IGF-1R antagonist (MK-0646) versus gemcitabine plus erlotinib with and without MK-0646 for advanced pancreatic adenocarcinoma

Abstract Background Binding of insulin-like growth factor-I (IGF-1) to its receptor (IGF-1R) initiates downstream signals that activate PI3K/Akt/mTOR and MEK/Erk pathways, which stimulate cancer cell proliferation and induce drug resistance. Cross talk between IGF-1R and epidermal growth factor rece...

Full description

Bibliographic Details
Main Authors: Reham Abdel-Wahab, Gauri R. Varadhachary, Priya R. Bhosale, Xuemei Wang, David R. Fogelman, Rachna T. Shroff, Michael J. Overman, Robert A. Wolff, Milind Javle
Format: Article
Language:English
Published: BMC 2018-05-01
Series:Journal of Hematology & Oncology
Subjects:
MK-0646
Gemcitabine
Erlotinib
Advanced pancreatic adenocarcinoma
Online Access:http://link.springer.com/article/10.1186/s13045-018-0616-2

Internet

http://link.springer.com/article/10.1186/s13045-018-0616-2

Similar Items